MOR-209/ES414

N/A

Report date: 2026/03/19 16:46:51

Base Information

Drug NameMOR-209/ES414

Drug Alias NameAnti-PSMA-X-Anti-CD3-ADAPTIR moleculeAPVO-414MOR-209ES-414MOR209

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsProstate-Specific Membrane Antigen inhibitors

TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEmergent

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMorphosys Ag Aptevo Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A